PMID- 28399537
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20220318
IS  - 1423-0356 (Electronic)
IS  - 0025-7931 (Print)
IS  - 0025-7931 (Linking)
VI  - 93
IP  - 6
DP  - 2017
TI  - Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary 
      Fibrosis Who Received Pirfenidone.
PG  - 415-423
LID - 10.1159/000468546 [doi]
AB  - BACKGROUND: Gastroesophageal reflux disease is a potential risk factor for 
      idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid 
      therapy (AAT) is under debate. OBJECTIVE: To evaluate the effect of AAT on IPF 
      progression in pirfenidone-treated patients. METHODS: This post hoc analysis 
      included patients with IPF who received pirfenidone in 3 trials (CAPACITY 
      [PIPF-004/PIPF-006] and ASCEND [PIPF-016]). Pulmonary function, exercise 
      tolerance, survival, hospitalizations, and adverse events (AEs) over 52 weeks 
      were analyzed by baseline AAT use. Disease progression was defined as a decrease 
      in forced vital capacity (FVC) of >/=10%, a decrease in 6-min walking distance of 
      >/=50 m, or death over 1 year. RESULTS: Of 623 patients, 44% received AAT. No 
      significant differences were found at 52 weeks (AAT versus non-AAT, respectively) 
      in disease progression (24.9 vs. 30.6%; p = 0.12), all-cause mortality rate (2.9 
      vs. 4.0%; p = 0.47), IPF-related mortality rate (1.1 vs. 2.0%; p = 0.37), 
      all-cause hospitalization rate (16.1 vs. 18.3%; p = 0.48), or mean change in 
      percent FVC (-2.7 vs. -3.1%; p = 0.44). A relative, but not absolute, FVC decline 
      of >/=10% favored AAT (15 vs. 22%; p = 0.03). Severe gastrointestinal AEs (3.7 vs. 
      0.9%; p = 0.015) and severe pulmonary infections (3.7 vs. 1.1%; p = 0.035) were 
      more frequent with AAT. CONCLUSIONS: AAT and pirfenidone had outcomes comparable 
      to those of pirfenidone alone in patients with IPF, underscoring the need for 
      prospective trials to elucidate the role of AAT with or without antifibrotic 
      drugs as a treatment for IPF.
CI  - (c) 2017 The Author(s) Published by S. Karger AG, Basel.
FAU - Kreuter, Michael
AU  - Kreuter M
AD  - Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory 
      Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, 
      Germany.
FAU - Spagnolo, Paolo
AU  - Spagnolo P
FAU - Wuyts, Wim
AU  - Wuyts W
FAU - Renzoni, Elisabetta
AU  - Renzoni E
FAU - Koschel, Dirk
AU  - Koschel D
FAU - Bonella, Francesco
AU  - Bonella F
FAU - Maher, Toby M
AU  - Maher TM
FAU - Kolb, Martin
AU  - Kolb M
FAU - Weycker, Derek
AU  - Weycker D
FAU - Kirchgassler, Klaus-Uwe
AU  - Kirchgassler KU
FAU - Costabel, Ulrich
AU  - Costabel U
LA  - eng
PT  - Journal Article
DEP - 20170412
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Antacids)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Pyridones)
RN  - D7NLD2JX7U (pirfenidone)
SB  - IM
MH  - Aged
MH  - Antacids/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Cause of Death
MH  - Disease Progression
MH  - Exercise Tolerance/physiology
MH  - Female
MH  - Gastroesophageal Reflux/complications/*drug therapy
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Idiopathic Pulmonary Fibrosis/complications/*drug 
      therapy/mortality/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Mortality
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Pyridones/*therapeutic use
MH  - Respiratory Function Tests
MH  - Survival Rate
MH  - Vital Capacity
MH  - Walk Test
PMC - PMC5452370
OTO - NOTNLM
OT  - Antacid therapy
OT  - Gastroesophageal reflux disease
OT  - Idiopathic pulmonary fibrosis
OT  - Pirfenidone
OT  - Progression-free survival
EDAT- 2017/04/12 06:00
MHDA- 2018/03/23 06:00
PMCR- 2017/04/12
CRDT- 2017/04/12 06:00
PHST- 2017/01/13 00:00 [received]
PHST- 2017/03/06 00:00 [accepted]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 00:00 [pmc-release]
AID - 000468546 [pii]
AID - res-0093-0415 [pii]
AID - 10.1159/000468546 [doi]
PST - ppublish
SO  - Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.